Higasa Satoshi, Tokugawa Tazuko, Sawada Akihiro
Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine.
Rinsho Ketsueki. 2018;59(10):2222-2232. doi: 10.11406/rinketsu.59.2222.
von Willebrand disease (VWD) is an inherited bleeding disorder resulting from either a quantitative or a qualitative deficiency in the plasma glycoprotein von Willebrand factor (VWF). A diagnosis of VWD can be made when a patient presents with appropriate bleeding and VWF <30 IU/dl. However, persons with VWF levels of 30-50 IU/dl cannot be precluded from the diagnosis of VWD. Desmopressin acetate (DDAVP) or VWF-containing factor VIII (pdVWF/FVIII) concentrate is used for treating VWD. The effect of DDAVP varies among individuals; a trial should be performed while in a nonbleeding state. For patients in whom DDAVP is invalid or those that require long-term management of hemostasis, pdVWF/FVIII is administered. The treatment of the hype rmenorrhea is the hope of every pregnant patient with VWD. When a patient with VWD becomes pregnant, VWF and FVIII should be regularly monitored throughout pregnancy. During childbirth, pdVWF/FVIII concentrate should be administered to achieve VWF and FVIII levels of ≥50 IU/dl before delivery.
血管性血友病(VWD)是一种遗传性出血性疾病,由血浆糖蛋白血管性血友病因子(VWF)的数量或质量缺陷引起。当患者出现适当出血且VWF<30 IU/dl时,可诊断为VWD。然而,VWF水平为30 - 50 IU/dl的人不能排除VWD的诊断。醋酸去氨加压素(DDAVP)或含VWF的凝血因子VIII(pdVWF/FVIII)浓缩物用于治疗VWD。DDAVP的效果因人而异;应在非出血状态下进行试验。对于DDAVP无效的患者或需要长期止血管理的患者,给予pdVWF/FVIII。治疗月经过多是每位患有VWD的孕妇的期望。当患有VWD的患者怀孕时,应在整个孕期定期监测VWF和FVIII。分娩期间,应给予pdVWF/FVIII浓缩物,以在分娩前使VWF和FVIII水平≥50 IU/dl。